| Absolute dose | Dose (mg/kg) | Animal | Number | Diameter | Length | Characteristics | Exposure form | Exposure time | Effects | Type |
| — | 0,064 | Rat | 8–10 | 0,9–1,7 nm | <1 μm | — | Tube feed | 1 dose, 24 hrs | Modified nucleotides in the DNA of the lung and liver | SWCNT | 10 μg | 0,3 | Mouse | — | — | — | Unfunctionalized | Intratracheal | 1 dose | No significant effects | SWCNT | 10 μg | 0,4 | Mouse | — | 0,7–1,5 nm | 1 μm | — | Pharyngeal instillation | 1 dose, 60 days | Damage to mitochondrial DNA in the aorta | SWCNT | — | 0,64 | Rat | 8–10 | 0,9–1,7 nm | <1 μm | — | Tube feed | 1 dose, 24 hrs | Modified nucleotides in the DNA of the lung and liver | SWCNT | — | 1 | Rat | 8 | 1,2–1,6 nm | 2–5 nm | — | Intratracheal | 2 doses over 4 weeks | Modified baroreflex, the influence of autonomic cardiovascular control | SWCNT | 40 μg | 1,3 | Mouse | — | — | — | Unfunctionalized | Intratracheal | 1 dose | Increase of creatine kinase, cardiac fibre degeneration | SWCNT | 40 μg | 1,3 | Mouse | — | — | — | Acid-functionalized | Intratracheal | 1 dose | Significant increase in size of infarction, creatine kinase, cardiac fibre degeneration | SWCNT | 10 μg | 1,3 | Mouse | — | — | — | Acid-functionalized | Intratracheal | 1 dose | No significant effects | SWCNT | 40 μg | 1,4 | Mouse | — | 0,7–1,5 nm | 1 μm | — | Pharyngeal instillation | 1 dose, 60 days | Damage to mitochondrial DNA | SWCNT | 40 μg | 1,5 | Mouse | — | 0,8–1,2 nm | 0,1–1 μm | 8,8 wt% iron | Pharyngeal aspiration | 4 h | Local and systemic effect on inflammatory parameters | SWCNT | 40 μg | 1,5 | Mouse | — | 80 nm | 10–20 μm | 0,2% wt% iron | Pharyngeal aspiration | 4 h | Local and systemic effect on inflammatory parameters | MWCNT | 20 μg × 4 | 2,8 | Mouse | — | 0,7–1,5 nm | 1 μm | — | Pharyngeal instillation | 4 doses over 8 weeks | Atherosclerosis was increased in ApoE−/− transgenic mice Plaque formation in aorta, mtDNA damage | SWCNT |
|
|